Ann: Sygenus shows longer lasting effect on pain than morphine, page-13

Hi @findingnemo, yes the PR/Communication has long been an issue / bone of contention with RGS but they seem to have realised they do not have that much control over SP fluctuations. We all know that ASX does not attract as much money as property development, and biotechs are no longer the darlings of investors: return on investment is much longer than some thought. Therefore SP fluctuations are very often dictated by low volumes and almost irrational trends.

Having said this, a few biotechs have fared better than others: VLA has had strings of solid news over time and their SP has had strong re-valuation.

In RGS case, what strikes me most is that Sygenus was mainly presented around Acne applications in the company FY17 presentation (August 2017) and yesterday's announcement is a coup both in terms of market applications (pain management, post op, etc) and PR: bold assessment of Sygenus results compared to well known morphine.

The company step by step strategy is impressive:

1. Fixing financials: reducing costs and finding an investing partner (AGC)
2. Steady research and product pipelines in 3 areas:
- Allogenic stem cell therapies for OA & inflammation,
- Immuno therapy for oncology,
- Secretions for inflammation (and now pain)
3. Keeping (so far) both animal and human health pathways to market i.e. faster routes (animal) and stronger income streams (human)

Yesterday's announcement is - in this context - the trigger point to a re-positionning of the company from a good Australian biotech to a major R&D health company.

How good PR/Com can be derived from this? Well, we will see but I am not convinced it's RGS' job to spend time and money on PR right now. More good news on trials is all I am hoping for.